Anastasios Gianakakos
CIK 1413822 · President & CEO · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MYOK price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KARD | President & CEO | 9,806,633 | $12.74 | $124.94M | $0 | 1 | 2026-06-22 |
| LianBio (LIAN) Delisted | Director | 363,253 | $0.32 | $115.9K | $0 | 4 | 2024-02-20 |
| MyoKardia, Inc. (MYOK) Delisted | President and CEO | 624,790 | — | — | -$13.62M | 64 | 2020-07-07 |
| MAP Pharmaceuticals, Inc. (MAPP) Delisted | SVP, Chief Business Officer | 0 | $28.11 | $0 | -$3.84M | 53 | 2013-03-04 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| KARD | Direct | 49,821 | 0.5% | 2026-06-22 |
| By AEG 2021 Trust | 5,665,090 | 57.8% | 2026-06-22 | |
| By KCM 2023 Trust | 2,422,520 | 24.7% | 2026-06-22 | |
| By MJA Legacy Trust dated May 6, 2020 | 1,165,732 | 11.9% | 2026-06-22 | |
| By spouse | 498,692 | 5.1% | 2026-06-22 | |
| By Katina Mandas 2024 Qualified Annuity Trust dated April 29, 2024 | 4,778 | 0.0% | 2026-06-22 | |
| Total | 9,806,633 | |||
| LIAN | Direct | 53,630 | 14.8% | 2024-02-20 |
| By Trust | 309,623 | 85.2% | 2024-02-20 | |
| Total | 363,253 | |||
| MYOK | Direct | 19,122 | 3.1% | 2020-07-07 |
| By Reporting Person's Trust 4 | 300,000 | 48.0% | 2020-07-07 | |
| By Reporting Person's Trust 2 | 129,407 | 20.7% | 2020-07-07 | |
| By Trust 2 | 53,087 | 8.5% | 2020-07-07 | |
| By Trust 1 | 53,087 | 8.5% | 2020-07-07 | |
| By Trust 3 | 53,087 | 8.5% | 2020-07-07 | |
| By reporting Person's Trust 6 | 10,000 | 1.6% | 2020-07-07 | |
| By Reporting Person's Trust 5 | 7,000 | 1.1% | 2020-07-07 | |
| Total | 624,790 | |||
| No longer reported | ||||
| By Reporting Person's Trust 3 | 0 | — | last 2020-04-20 | |
| By The James Gianakakos 2015 Irrevocable Trust Dtd 9/26/2015 | 12,200 | — | last 2018-02-07 | |
| By The Alexander Gianakakos 2015 Irrevocable Trust dtd 9/26/2015 | 12,200 | — | last 2018-02-07 | |
| By The Gianakakos Family Revocable Trust DTD 11/02/2006 | 85,973 | — | last 2018-02-07 | |
| By The Tassos Gianakakos 2018 Annuity Trust dtd 1/6/2018 | 500,000 | — | last 2018-02-07 | |
| By The Emmanuel Gianakakos 2015 Irrevocable Trust Dtd 9/26/2015 | 12,200 | — | last 2018-02-07 | |
| By Reporting Person's Trust | 181,169 | — | last 2018-01-16 | |
| Tassos Gianakakos 2015 Annuity Trust, dated September 25, 2015 Trust |
181,169 | — | last 2017-11-03 | |
| By Trust | 181,169 | — | last 2017-03-22 | |
Recent Filings · Page 9 of 13
123 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-01-20 | MAP Pharmaceuticals, Inc. (MAPP) Delisted | Mixed | — | -$58.8K | EDGAR |
| 2011-12-14 | MAP Pharmaceuticals, Inc. (MAPP) Delisted | Mixed | +8,658 | -$123.4K | EDGAR |
| 2011-08-03 | MAP Pharmaceuticals, Inc. (MAPP) Delisted | Mixed | — | -$21.8K | EDGAR |
| 2011-07-05 | MAP Pharmaceuticals, Inc. (MAPP) Delisted | Mixed | — | -$22.8K | EDGAR |
| 2011-06-03 | MAP Pharmaceuticals, Inc. (MAPP) Delisted | Mixed | — | -$24.3K | EDGAR |
| 2011-05-10 | MAP Pharmaceuticals, Inc. (MAPP) Delisted | Mixed | — | -$81.3K | EDGAR |
| 2011-05-03 | MAP Pharmaceuticals, Inc. (MAPP) Delisted | Mixed | — | -$22.1K | EDGAR |
| 2011-04-04 | MAP Pharmaceuticals, Inc. (MAPP) Delisted | Mixed | — | -$19.9K | EDGAR |
| 2011-03-02 | MAP Pharmaceuticals, Inc. (MAPP) Delisted | Mixed | — | -$22.7K | EDGAR |
| 2011-02-03 | MAP Pharmaceuticals, Inc. (MAPP) Delisted | Mixed | — | -$36.8K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).